PD-L1 is upregulated in 40%-60% of cases, making a case for immunotherapy, and we've seen some recent data regarding that." He noted that cemiplimab is FDA approved for locally advanced or ...

“Precision immunotherapy has been an elusive dream ... the first site selected to test the anti-PD-1 monoclonal antibody cemiplimab in a phase II clinical trial 2 for high-risk cutaneous ...

The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech’s mRNA cancer immunotherapy BNT111, which is designed to stimulate immune responses against four ...

These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab. Cemiplimab acts as a checkpoint inhibitor by binding to PD-1 ...

Brain tumours cannot be treated with immunotherapy alone as they are ... with Sanofi’s Libtayo (cemiplimab), with data from the 36-patient trial due this year or next. AstraZeneca plans to ...

Nine patients underwent the injections into their tumors, having failed other immunotherapy treatments like pembrolizumab or cemiplimab. The treatment was well tolerated, and there were no ...